Oleogel S10

Drug Profile

Oleogel S10

Alternative Names: AP 101; Betulin-based oleogel; Episalvan; Oleogel-S10; Sericare

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Birken GmbH
  • Developer Amryt Pharma
  • Class Herbal medicines; Skin disorder therapies; Triterpenes
  • Mechanism of Action Keratinocyte modulators; Transient receptor potential channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered Wounds
  • Phase III Burns
  • Phase II Actinic keratosis; Epidermolysis bullosa

Most Recent Events

  • 09 Dec 2016 Birken AG has been acquired by Amryt Pharma
  • 05 Dec 2016 Oleogel S10 receives Orphan Drug status for Epidermolysis bullosa in USA before December 2016
  • 05 Dec 2016 Amryt Pharma plans a phase III trial for Epidermolysis bullosa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top